Based on the previous promising anti-tumor activities of some morpholinosulfonyl isatin derivatives on HepG2 [22,23], we tested their anti-cancer activities against two hepatocellular carcinoma (HCC) cell lines: the HepG2 and Huh7 cell lines, which are different in their drug-metabolizing activities as well as their p53 expression. Here, TP53 is linked to hepatocellular carcinoma.